AD-HIES
MCID: HYP345
MIFTS: 54

Hyper-Ige Recurrent Infection Syndrome (AD-HIES) malady

Categories: Genetic diseases, Rare diseases, Immune diseases, Skin diseases, Blood diseases, Bone diseases

Aliases & Classifications for Hyper-Ige Recurrent Infection Syndrome

About this section

Aliases & Descriptions for Hyper-Ige Recurrent Infection Syndrome:

Name: Hyper-Ige Recurrent Infection Syndrome 52 12
Job Syndrome 11 24 25 54 70 39 68
Ad-Hies 23 48 24 25 54 70
Stat3 Deficiency 23 24 25 54
Job's Syndrome 11 24 25 13
Autosomal Dominant Hyper Ige Syndrome 23 48 24
Stat3-Deficient Hyper Ige Syndrome 23 24 25
Buckley Syndrome 25 54 70
Hyperimmunoglobulin E Recurrent Infection Syndrome, Autosomal Dominant 48 70
Hyper-Ige Recurrent Infection Syndrome, Autosomal Dominant 52 68
Hyperimmunoglobulin E Syndrome Type 1 54 70
Autosomal Dominant Hyper-Ige Syndrome 25 54
Hyperimmunoglobulin E Syndrome 11 27
Autosomal Dominant Hies 25 54
Hies Autosomal Dominant 48 70
 
Autosomal Dominant Hyperimmunoglobulin E Recurrent Infection Syndrome 25
Hyper-Ige Recurrent Infection Syndrome Autosomal Dominant 70
Autosomal Dominant Hyper-Ige Recurrent Infection Syndrome 25
Hyper-Immunoglobulin E Syndrome, Autosomal Dominant 68
Hyperimmunoglobulin E-Recurrent Infection Syndrome 54
Autosomal Dominant Hyperimmunoglobulin E Syndrome 54
Hyper Ig E Syndrome, Autosomal Dominant 48
Hyper-Ige Syndrome Autosomal Dominant 70
Stat3 Deficient Hyper Ige Syndrome 24
Ad Hyperimmunoglobulin E Syndrome 48
Autosomal Dominant Job Syndrome 25
Job Syndrome Autosomal Dominant 48
Job-Buckley Syndrome 25
Job’s Syndrome 23

Characteristics:

Orphanet epidemiological data:

54
job syndrome:
Inheritance: Autosomal dominant; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Infancy,Neonatal; Age of death: any age

HPO:

64
hyper-ige recurrent infection syndrome:
Inheritance: autosomal dominant inheritance
Onset and clinical course: infantile onset

GeneReviews:

23
Penetrance: intrafamilial variability is minimal and penetrance appears to be complete...


Classifications:



External Ids:

OMIM52 147060
Disease Ontology11 DOID:3261
MeSH39 D007589
Orphanet54 ORPHA2314
ICD10 via Orphanet31 D82.4
UMLS via Orphanet69 C2936739, C3489795
ICD1030 D82.4

Summaries for Hyper-Ige Recurrent Infection Syndrome

About this section
NIH Rare Diseases:48 Autosomal dominant hyper ige syndrome (ad-hies), formerly known as job syndrome, affects several body systems including the immune system. ad-hies is characterized by abnormally high levels of an immune system protein called immunoglobulin e (ige) in the blood.  signs and symptoms may include recurrent infections (e.g., pneumonia, skin infections), eczema, and occasionally bone and tooth abnormalities. the eczema and skin infections may cause rashes, blisters, collections of pus (abscesses), open sores, and scaling of the skin. some cases of ad-hies are caused by mutations in the stat3 gene. in other cases, the cause is unknown. last updated: 7/14/2015

MalaCards based summary: Hyper-Ige Recurrent Infection Syndrome, also known as job syndrome, is related to hyper-ige recurrent infection syndrome, autosomal recessive and hyper ige syndrome, and has symptoms including Array, Array and Array. An important gene associated with Hyper-Ige Recurrent Infection Syndrome is STAT3 (Signal Transducer And Activator Of Transcription 3), and among its related pathways are Jak/STAT Signaling Pathway and Interleukin-11 Signaling Pathway. Affiliated tissues include skin, bone and lung, and related mouse phenotypes are hematopoietic system and immune system.

UniProtKB/Swiss-Prot:70 Hyperimmunoglobulin E recurrent infection syndrome, autosomal dominant: A rare disorder of immunity and connective tissue characterized by immunodeficiency, chronic eczema, recurrent Staphylococcal infections, increased serum IgE, eosinophilia, distinctive coarse facial appearance, abnormal dentition, hyperextensibility of the joints, and bone fractures.

Genetics Home Reference:25 Autosomal dominant hyper-IgE syndrome (AD-HIES), also known as Job syndrome, is a condition that affects several body systems, particularly the immune system. Recurrent infections are common in people with this condition. Affected individuals tend to have frequent bouts of pneumonia, which are caused by certain kinds of bacteria that infect the lungs and cause inflammation. These infections often result in the formation of air-filled cysts (pneumatoceles) in the lungs. Recurrent skin infections and an inflammatory skin disorder called eczema are also very common in AD-HIES. These skin problems cause rashes, blisters, accumulations of pus (abscesses), open sores, and scaling.

OMIM:52 Hyper-IgE recurrent infection syndrome is a primary immunodeficiency disorder characterized by chronic eczema,... (147060) more...

GeneReviews for NBK25507

Related Diseases for Hyper-Ige Recurrent Infection Syndrome

About this section

Graphical network of the top 20 diseases related to Hyper-Ige Recurrent Infection Syndrome:



Diseases related to hyper-ige recurrent infection syndrome

Symptoms & Phenotypes for Hyper-Ige Recurrent Infection Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

147060

Clinical features from OMIM:

147060

Human phenotypes related to Hyper-Ige Recurrent Infection Syndrome:

 54 64 (show all 46)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the teeth54 Frequent (79-30%)
2 cleft palate64 54 Frequent (79-30%) HP:0000175
3 gingivitis64 54 Frequent (79-30%) HP:0000230
4 abnormality of the face54 Frequent (79-30%)
5 chronic otitis media64 54 Frequent (79-30%) HP:0000389
6 wide nasal bridge64 54 Frequent (79-30%) HP:0000431
7 deeply set eye64 54 Frequent (79-30%) HP:0000490
8 delayed eruption of teeth64 54 Frequent (79-30%) HP:0000684
9 osteopenia64 54 Frequent (79-30%) HP:0000938
10 eczema64 54 Very frequent (99-80%) HP:0000964
11 skin rash64 54 Very frequent (99-80%) HP:0000988
12 pruritus64 54 Very frequent (99-80%) HP:0000989
13 craniosynostosis64 54 Occasional (29-5%) HP:0001363
14 abnormality of the hair64 54 Frequent (79-30%) HP:0001595
15 paronychia64 54 Frequent (79-30%) HP:0001818
16 eosinophilia64 54 Frequent (79-30%) HP:0001880
17 fever64 54 Occasional (29-5%) HP:0001945
18 recurrent respiratory infections64 54 Very frequent (99-80%) HP:0002205
19 aneurysm64 54 Occasional (29-5%) HP:0002617
20 scoliosis64 54 Frequent (79-30%) HP:0002650
21 lymphoma64 54 Occasional (29-5%) HP:0002665
22 recurrent infections54 Very frequent (99-80%)
23 osteomyelitis64 54 Occasional (29-5%) HP:0002754
24 recurrent fractures64 54 Frequent (79-30%) HP:0002757
25 increased ige level64 54 Very frequent (99-80%) HP:0003212
26 joint hyperflexibility64 54 Frequent (79-30%) HP:0005692
27 dystrophic fingernails64 54 Frequent (79-30%) HP:0008391
28 prominent forehead64 54 Frequent (79-30%) HP:0011220
29 generalized abnormality of skin64 54 Very frequent (99-80%) HP:0011354
30 cough64 54 Frequent (79-30%) HP:0012735
31 cellulitis64 54 Occasional (29-5%) HP:0100658
32 atelectasis64 54 Very frequent (99-80%) HP:0100750
33 papule64 54 Frequent (79-30%) HP:0200034
34 skin vesicle64 54 Occasional (29-5%) HP:0200037
35 skin ulcer64 54 Very frequent (99-80%) HP:0200042
36 high palate64 HP:0000218
37 coarse facial features64 HP:0000280
38 hypertelorism64 HP:0000316
39 wide nose64 HP:0000445
40 eczematoid dermatitis64 HP:0000976
41 joint hypermobility64 HP:0001382
42 frontal bossing64 HP:0002007
43 recurrent staphylococcus aureus infections64 HP:0002726
44 recurrent fungal infections64 HP:0002841
45 recurrent sinopulmonary infections64 HP:0005425
46 persistence of primary teeth64 HP:0006335

MGI Mouse Phenotypes related to Hyper-Ige Recurrent Infection Syndrome according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053977.9DOCK8, IL17A, IRAK4, STAT3, STK4, TYK2
2MP:00053877.1DOCK8, IL17A, IRAK4, STAT3, STK4, TYK2

Drugs & Therapeutics for Hyper-Ige Recurrent Infection Syndrome

About this section

Drugs for Hyper-Ige Recurrent Infection Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 138)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
HaloperidolapprovedPhase 4, Phase 114752-86-83559
Synonyms:
1-(3-P-Fluorobenzoylpropyl)-4-P-chlorophenyl-4-hydroxypiperidine
4'-Fluoro-4-(4-(P-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
4-(4-(Para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
5-21-02-00377 (Beilstein Handbook Reference)
52-86-8
AB00052008
AC-19691
AC1L1G7K
AC1Q77Z0
AKOS000280660
ALDO
Aldo
Aloperidin
Aloperidol
Aloperidolo
Aloperidolo [DCIT]
Aloperidolo [Italian]
Aloperidon
Apo-Haloperidol
BIDD:GT0128
BPBio1_000144
BPBio1_001231
BRD-K67783091-001-04-8
BRD-K67783091-001-05-5
BRN 0331267
BSPBio_000130
BSPBio_002096
Bio-0705
Biomol-NT_000035
Bioperidolo
Brotopon
C01814
C21H23ClFNO2
CAS-52-86-8
CCRIS 1630
CHEBI:5613
CHEMBL54
CID3559
D00136
D006220
DB00502
DivK1c_000654
Dozic
Dozix
EINECS 200-155-6
EU-0100583
Einalon S
Eukystol
Fortunan
Galoperidol
H 1512
H0912
H1512_SIGMA
HMS1568G12
HMS1920D03
HMS2089M15
HMS2091J09
HMS502A16
HSDB 3093
Haldol
Haldol Decanoate
Haldol La
Haldol Solutab
Halidol
Halojust
Halol
Halopal
Haloperido
Haloperidol (JP15/USP)
Haloperidol (JP15/USP/INN)
Haloperidol Decanoate
Haloperidol Intensol
Haloperidol Lactate
Haloperidol [USAN:INN:BAN:JAN]
Haloperidolum
Haloperidolum [INN-Latin]
Halopidol
Halopoidol
Halosten
I14-13404
I14-14165
IDI1_000654
 
KBio1_000654
KBio2_001341
KBio2_002390
KBio2_003909
KBio2_004958
KBio2_006477
KBio2_007526
KBio3_001316
KBio3_002869
KBioGR_000980
KBioGR_002390
KBioSS_001341
KBioSS_002395
Keselan
L000288
LS-48311
Lealgin Compositum
Lealgin compositum
Linton
Lopac-H-1512
Lopac0_000583
MLS000028450
MLS001146904
McN-JR-1625
Mixidol
MolPort-000-883-311
NCGC00015500-01
NCGC00015500-02
NCGC00015500-06
NCGC00015500-14
NCGC00016234-01
NCGC00023875-02
NCGC00023875-04
NCGC00023875-05
NCGC00023875-06
NCGC00023875-07
NCGC00023875-08
NCGC00023875-09
NINDS_000654
NSC 170973
NSC 615296
NSC170973
NSC615296
Novo-Peridol
Oprea1_509923
Pekuces
Peluces
Peridol
Pernox
Pms Haloperidol
Prestwick0_000115
Prestwick1_000115
Prestwick2_000115
Prestwick3_000115
Prestwick_250
Probes1_000255
Probes2_000296
QTL1_000042
R 1625
R-1625
S1920_Selleck
SMR000058303
SPBio_001236
SPBio_002069
SPECTRUM1500325
Serenace
Serenase
Serenelfi
Sernas
Sernel
Sigaperidol
Spectrum2_001268
Spectrum3_000448
Spectrum4_000570
Spectrum5_000788
Spectrum_000861
Tocris-0931
UNII-J6292F8L3D
Ulcolind
Uliolind
Vesalium
WLN: T6NTJ A3VR DF& DQ DR DG
cMAP_000037
gamma-(4-(P-Chlorophenyl)-4-hydroxpiperidino)-P-fluorbutyrophenone
haloperidol
2
DopamineapprovedPhase 4, Phase 1383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
3
Risperidoneapproved, investigationalPhase 4, Phase 1492106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
 
NCGC00015883-01
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
4
Aspirinapproved, vet_approvedPhase 4115250-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalicylsäure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide acetylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
Entericin
Enterophen
 
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
acide 2-(acétyloxy)benzoïque
acide acétylsalicylique
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
salicylic acid acetate
ácido acetilsalicílico
5
CilostazolapprovedPhase 410673963-72-12754
Synonyms:
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
73963-72-1
89332-50-3
AC-4334
AC1L1EE2
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRN 3632107
BSPBio_002759
C 0737
C045645
C0737_SIGMA
C20H27N5O2
CHEBI:31401
CHEMBL799
CID2754
CL23867
CPD000058428
Cilostazol (JP15/USAN/INN)
Cilostazol [INN:JAN]
Cilostazole
Cilostazolum
Cilostazolum [INN-Latin]
D01896
DB01166
EU-0100218
HMS1922N15
HMS2093M14
KBio3_002259
KBioGR_001184
 
LS-142693
Lopac-C-0737
Lopac0_000218
MLS000028470
MLS000758281
MLS000759507
MLS001076067
MLS002153891
MolPort-001-758-007
NCGC00015207-01
NCGC00015207-02
NCGC00015207-06
NCGC00015207-10
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
OPC 13013
OPC 21
OPC-13013
OPC-21
Otsuka brand of cilostazol
Pletaal
Pletal
Pletal (TN)
Pletal, Cilostazol
S1294_Selleck
SAM001246734
SAM001247085
SMR000058428
SPBio_001256
SPECTRUM1505230
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
TL8005113
Tocris-1692
UNII-N7Z035406B
ZINC01552174
cilostazol
6
ZiprasidoneapprovedPhase 4145146939-27-760854
Synonyms:
138982-67-9 (hydrochloride monohydrate)
146939-27-7
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
6-chloro-5-[2-[4-(7-thia-8-azabicyclo[4.3.0]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one
AC1L1U27
Ambap122883-93-6
BIDD:GT0042
C07568
C21H21ClN4OS
CHEBI:10119
CHEMBL708
CID60854
CP 88059
CP 88059-01
CP-88,059
CP-88,059-01
CP-88,059-1
CP-88059-1
CPD000466328
D08687
DB00246
 
Geodon
Geodon Oral
I14-0766
L000659
LS-83744
MLS000759435
MolPort-003-850-885
SAM001246607
SMR000466328
TL8000889
UNII-6UKA5VEJ6X
Zeldox
Zipradon
Zipradon (TN)
Ziprasidona
Ziprasidone
Ziprasidone (INN)
Ziprasidone [INN:BAN]
Ziprasidone hydrochloride
Ziprasidone mesylate trihydrate
Ziprasidonum
ziprasidona
ziprasidonum
ziprazidone
7
FluspirileneapprovedPhase 491841-19-63396
Synonyms:
1-Phenyl-4-oxo-8-(4,4-bis(4-fluorophenyl)butyl)-1,3,8-triazaspiro(4,5)decane
1841-19-6
5-26-04-00097 (Beilstein Handbook Reference)
8-(4,4-Bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro-(4.5)decan-4-one
8-[4,4-bis (p-fluorophenyl)butyl]- 1-phenyl-1,3,8-triazino[4,5]decan-4-one
8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[4,4-bis(4-fluorophenyl)butyl]-4-phenyl-2,4,8-triazaspiro[4.5]decan-1-one
8-[4,4-bis(p-Fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4.5]decan-4-one
AB00513956
AC1L1FUB
BPBio1_000828
BRD-K77947974-001-04-9
BRN 0633853
BSPBio_000752
BSPBio_001343
Bio-0707
C29H31F2N3O
CAS-1841-19-6
CHEMBL46516
CID3396
D02629
DB04842
EINECS 217-418-6
EU-0100518
F-100
F100_SIGMA
Fluspirilen
Fluspirilene
Fluspirilene (USAN/INN)
Fluspirilene [USAN:INN:BAN]
Fluspirileno
Fluspirileno [INN-Spanish]
Fluspirileno [inn-spanish]
Fluspirilenum
Fluspirilenum [INN-Latin]
 
Fluspirilenum [inn-latin]
HMS1570F14
HMS1791D05
HMS1989D05
HMS2089C15
Imap
Imap (TN)
L001195
LS-154759
Lopac-F-100
Lopac0_000518
MLS000069357
MLS001333730
McN-JR-6218
MolPort-002-540-769
NCGC00015424-01
NCGC00015424-02
NCGC00015424-08
NCGC00016595-01
NCGC00093913-01
NCGC00093913-02
NCGC00093913-03
NCGC00093913-04
NCGC00093913-05
Oprea1_804941
Prestwick0_000906
Prestwick1_000906
Prestwick2_000906
Prestwick3_000906
R 6218
R6218
Redeptin
SMR000058304
SPBio_002951
Spirodiflamine
spiropiperidine analogue, 1
8
Olanzapineapproved, investigationalPhase 4399132539-06-14585
Synonyms:
132539-06-1
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC-665
AC1L1IHS
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
LS-152313
LY 170053
LY-170052
 
LY-170053
Lanzac
Lilly brand of olanzapine
MLS000759457
MLS001165781
MLS001195646
MLS001424057
Midax
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
Olanzapina
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa Zydis
olanzapina
olanzapine
olanzapinum
9
SulpirideapprovedPhase 44415676-16-15355
Synonyms:
( inverted question mark)-Sulpiride
(+-)-Sulpiride
(+/-)-Sulpiride
(?)-Sulpiride
(RS)-(+/-)-sulpiride
15676-16-1
23672-07-3
5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide
5-22-08-00105 (Beilstein Handbook Reference)
AC-12181
AC1L1K62
AKOS004912732
Abilit
Aiglonyl
Alimoral
Allphar Brand of Sulpiride
Almirall Brand of Sulpiride
Areu Brand of Sulpiride
Arminol
BPBio1_000233
BPBio1_000463
BPBio1_001255
BRD-A55272860-001-03-9
BRD-A55272860-001-04-7
BRN 0494008
BSPBio_000211
Bio-0717
Biomol-NT_000037
Biomol-NT_000162
C15H23N3O4S
CCRIS 4248
CHEMBL26
CID5355
Calmoflorine
Centrum Brand of Sulpiride
Championyl
Coolspan
D01226
D013469
DB00391
Darleton
Deponerton
Desisulpid
Desitin Brand of Sulpiride
Desmenat
Digton
DivK1c_000278
Dobren
Dogmatil
Dogmatyl
Dogmatyl (TN)
Dolmatil
Dolorgiet Brand of Sulpiride
Dresent
EINECS 239-753-7
EU-0001755
EU-0101050
Eglonil
Eglonyl
Ekilid
Enimon
Equilid
Erempharma Brand of Sulpiride
Eusulpid
Fardalan
Fidelan
Fumouzer Brand of Sulpiride
Guastil
HMS1568K13
HMS500N20
Hennig Brand of Sulpiride
Hexal Brand of Sulpiride
Hoechst Brand of Sulpiride
Hormosan Brand of Sulpiride
I06-0054
IDI1_000278
Isnamide
KBio1_000278
Krewel Brand of Sulpiride
Kylistro
L000579
LS-20058
LS-20059
Lebopride
Levobren
Levopraid
Levosulpirida
Levosulpirida [INN-Spanish]
 
Levosulpiride
Levosulpiride [INN]
Levosulpiridum
Levosulpiridum [INN-Latin]
Lisopiride
Lopac0_001050
MLS000069434
MLS001306443
Magnetic resonance imaging sulpiride
Mariastel
Meresa
Miradol
Mirbanil
Misulvan
MolPort-002-070-475
N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide
N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-O-anisamide
N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide
NCGC00015966-04
NCGC00015966-08
NCGC00024852-02
NCGC00024852-03
NCGC00024852-04
NCGC00024852-05
NINDS_000278
Neogama
Norestran
Normum
Nufarol
Omiryl
Omperan
Oprea1_602476
Ozoderpin
Pharmacia Brand of Sulpiride
Pontiride
Prestwick0_000056
Prestwick1_000056
Prestwick2_000056
Prestwick3_000056
Prestwick_431
Psicocen
Psicofarma Brand of Sulpiride
Pyrikappl
Pyrkappl
R. D. 1403
R.D. 1403
RD 1403
RV-12309
Restful
Rosemont Brand of Sulpiride
S 8010
S-(-)-Sulpiride
S8010_SIGMA
SMR000038923
SPBio_002132
STK368596
Sanofi Synthelabo Brand of Sulpiride
Sanofi-Synthelabo Brand of Sulpiride
Sernevin
Splotin
Spyfarma Brand of Sulpiride
Stamonevrol
Sulp
Sulperide
Sulpirid
Sulpirida
Sulpirida [INN-Spanish]
Sulpiride (JP15/USAN/INN)
Sulpiride [USAN:INN:BAN:JAN]
Sulpiridum
Sulpiridum [INN-Latin]
Sulpitil
Sulpivert
Sulpor
Sulpride
Sulpyrid
Suprium
Sursumid
Synedil
Tepavil
Uriach Brand of Sulpiride
Valirem
Vertigo Meresa
Vertigo-Meresa
Zemorcon
nchembio873-comp17
sulpiride
vertigo neogama
vertigo-neogama
10
PimozideapprovedPhase 4112062-78-416362
Synonyms:
1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone
1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine
1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H- benzimidazol-2-one
1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone
1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one
1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine
1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
2062-78-4
3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one
5-24-02-00367 (Beilstein Handbook Reference)
AB00052215
AC1L27SR
AC1Q4M09
AC1Q4NM9
ASTA Medica Brand of Pimozide
Antalon
BCBcMAP01_000043
BIDD:GT0435
BPBio1_000304
BRD-K01292756-001-06-0
BRN 0729089
BSPBio_000276
BSPBio_001439
BSPBio_002941
C07566
C28H29F2N3O
CAS-2062-78-4
CCRIS 9172
CHEBI:8212
CHEMBL1423
CID16362
D00560
D010868
DB01100
DivK1c_000386
EINECS 218-171-7
EU-0100946
HMS1568N18
HMS1791H21
HMS1921H19
HMS1989H21
HMS2089C11
HMS2092F09
HMS501D08
Halomonth
IDI1_000386
Janssen Brand of Pimozide
KBio1_000386
KBio2_000925
KBio2_003493
KBio2_006061
KBio3_002441
KBioGR_000720
KBioSS_000925
L000494
LS-33236
Lopac-P-1793
Lopac0_000946
MLS000028410
 
MLS001077311
MLS002702058
McN-JR 6238
McN-JR-6238
MolPort-001-736-597
NCGC00015802-01
NCGC00015802-02
NCGC00015802-04
NCGC00015802-15
NCGC00016601-01
NCGC00022282-03
NCGC00024888-01
NCGC00024888-02
NCGC00024888-03
NCGC00024888-04
NCGC00024888-05
NCGC00024888-06
NCGC00024888-07
NCIMech_000356
NINDS_000386
NSC 170984
NSC170984
Neoperidole
Opiran
Orap
Orap (TN)
Orap forte
P 1793
P1793_SIGMA
Pharmascience Brand of Pimozide
Pimozida
Pimozida [INN-Spanish]
Pimozide
Pimozide (JAN/USP/INN)
Pimozide [USAN:INN:BAN:JAN]
Pimozidum
Pimozidum [INN-Latin]
Prestwick0_000308
Prestwick1_000308
Prestwick2_000308
Prestwick3_000308
Prestwick_395
Primozida
Primozida [INN-Spanish]
R 6238
R-6238
R6238
SMP1_000241
SMR000058385
SPBio_001211
SPBio_002495
SPECTRUM1501134
Spectrum2_001026
Spectrum3_001451
Spectrum4_000420
Spectrum5_001308
Spectrum_000445
Tocris-0937
UNII-1HIZ4DL86F
WLN: T56 BMVNJ D- DT6NTJ A3YR DF&R DF
pimozida
pimozide
11
PerphenazineapprovedPhase 49358-39-94748
Synonyms:
.gamma.-[4-(.beta.-Hydroxyethyl)piperazin-1-yl]propyl-2-chlorophenothiazine
1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina
1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina [Italian]
1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-phenothiazinyl)propyl)piperazine
1-(2-Hydroxyethyl)-4-[3-(2-chloro-10-phenothiazinyl)propyl]piperazine
1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-, trihydrochloride
2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol
2-(4-[3-(2-chloro-10H-Phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol
2-Chloro-10-(3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine
2-Chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine
2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl phenothiazine
2-Chloro-10-3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl phenothiazine
2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine
2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol
2-chloro-10-(3-(4-(2-Hydroxyethyl)piperazin-1-yl)propyl)phenothiazine
2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol
2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol
4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-piperazineethanol
4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol
4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol
4-[3-(2-chloro-10H-Phenothiazin-10-yl)propyl]-1-piperazineethanol
58-39-9
AB00052390
AC-12196
AC1L1IVB
AI3-50151
AKOS000664046
Apo-Perphenazine
BAS 00139131
BIDD:GT0150
BPBio1_000188
BRD-K10995081-001-05-5
BSPBio_000170
BSPBio_002376
C07427
C21H26ClN3OS
CAS-58-39-9
CHEBI:8028
CHEMBL567
CID4748
CPD000058180
Chlorperphenazine
Chlorpiprazine
D00503
D010546
DB00850
Decentan
DivK1c_000880
EINECS 200-381-5
EU-0072164
EU-0100930
Emesinal
Etaperazin
Etaperazine
Ethaperazine
Etrafon-A
Etrafon-Forte
F-Mon
F-mon
Fentazin
HMS1568I12
HMS1922M14
HMS2093M15
HMS502L22
HSDB 3379
I06-1508
IDI1_000880
KBio1_000880
KBio2_002090
KBio2_004658
 
KBio2_007226
KBio3_001596
KBioGR_001445
KBioSS_002090
L000919
LS-112185
Lopac-P-6402
Lopac0_000930
MLS000069637
MLS001146929
MolPort-001-727-942
NCGC00015826-01
NCGC00015826-02
NCGC00015826-03
NCGC00015826-06
NCGC00015826-10
NCGC00024092-03
NCGC00024092-04
NCGC00024092-05
NCGC00024092-06
NINDS_000880
NSC 150866
NSC150866
Oprea1_603835
P 6402
P6402_SIGMA
PZC
Perfenazina
Perfenazina [INN-Spanish]
Perfenazina [Italian]
Perfenazine
Perphenan
Perphenazin
Perphenazine (JP15/USP/INN)
Perphenazine [INN:BAN:JAN]
Perphenazine [Trilafon]
Perphenazine maleate
Perphenazinum
Perphenazinum [INN-Latin]
Perphénazine
Prestwick0_000125
Prestwick1_000125
Prestwick2_000125
Prestwick3_000125
Prestwick_536
SAM002264637
SCH-3940
SMR000058180
SPBio_001603
SPBio_002109
SPECTRUM1503934
SR-01000000137-4
STK019818
STOCK1S-21551
Sch 3940
Spectrum2_001602
Spectrum3_000758
Spectrum4_000843
Spectrum5_001493
Spectrum_001610
Thilatazin
Tranquisan
Trifaron
Trilafon
Trilifan
Triphenot
UNII-FTA7XXY4EZ
WLN: T C666 BN ISJ EG B3- AT6N DNTJ D2Q
gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine
nchembio873-comp26
perphenazine
12
FluphenazineapprovedPhase 41669-23-83372
Synonyms:
1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine
1-(2-Hydroxyethyl)-4-[3-(trifluoromethyl-10-phenothiazinyl)propyl]piperazine
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9CI)
10-(3'-(4"-(beta-Hydroxyethyl)-1"-piperazinyl)-propyl)-3-trifluoromethylphenothiazine
10-(3'-(4''-(beta-Hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine
10-(3'-(4''-(beta-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine
10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine
2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol
2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethanol
2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-pipe razinyl)propyl)phenothiazine
2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine
2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol
2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol dihydrochloride
4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol
4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-Piperazineethanol
4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
4-[3-(2-Trifluoromethyl-10-phenothiazyl)-propyl]-1-piperazineethanol
47646-09-3
69-23-8
AB00053587
AC1L1FSB
AKOS001659031
Apo-Fluphenazine
BIDD:PXR0184
BPBio1_000352
BPBio1_001187
BRD-K55127134-001-01-7
BRD-K55127134-300-05-4
BSPBio_000320
BSPBio_003100
Bio-0775
Biomol-NT_000023
C07010
C22H26F3N3OS
CAS-146-56-5
CHEBI:136842
CHEBI:5123
CHEMBL726
CID3372
ChemDiv1_024180
D005476
D07977
DB00623
Dapotum
DivK1c_000511
EINECS 200-702-9
Elinol
FLUPHENAZINE
Flufenazin
Flufenazina
Flufenazina [DCIT]
Fluorfenazine
Fluorophenazine
Fluorphenazine
Fluphenazin
Fluphenazine (INN)
Fluphenazine Decanoate
Fluphenazine Hcl
Fluphenazine [INN:BAN]
Fluphenazine hydrochloride
Fluphenazinum
Fluphenazinum [INN-Latin]
Fluphénazine
Ftorphenazine
HMS2089C16
HMS655L02
 
HSDB 3334
Hydrochloride, Fluphenazine
IDI1_000511
KBio1_000511
KBio2_000769
KBio2_002386
KBio2_003337
KBio2_004954
KBio2_005905
KBio2_007522
KBio3_002320
KBio3_002865
KBioGR_001375
KBioGR_002386
KBioSS_000769
KBioSS_002391
L000257
LS-112565
Lopac-F-4765
Lopac0_000555
Modecate
Moditen (TN)
Moditen (Tabl or elixir)
Moditen Enanthate
Moditen Hcl
MolPort-001-727-938
NCGC00015436-01
NCGC00015436-02
NCGC00015436-03
NCGC00015436-08
NCGC00024429-03
NCGC00024429-04
NINDS_000511
NSC 62323
NSC62323
Pacinol
Permitil Concentrate
Phthorphenazine
Prestwick0_000320
Prestwick1_000320
Prestwick2_000320
Prestwick3_000320
Probes1_000254
Probes2_000295
Prolixin
Prolixin Concentrate
Prolixin Enanthate
Prolixine
S94
SPBio_001277
SPBio_002539
SQ 4918
SR-01000003048-5
STK050763
Sevinol
Siqualine
Siqualon
Spectrum2_001199
Spectrum3_001420
Spectrum4_000828
Spectrum5_001536
Spectrum_000289
Triflumethazine
UNII-S79426A41Z
Vespazine
Yespazine
cMAP_000035
nchembio873-comp68
13
Clopidogrelapproved, nutraceuticalPhase 4778120202-66-6, 113665-84-260606
Synonyms:
( )-(S)-Clopidogrel
(+)-(S)-Clopidogrel
(+)-Clopidogrel
(S)-Clopidogrel
(S)-Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate
113665-84-2
AC-19024
AC1L1TKZ
AC1Q41I9
BIDD:GT0284
BRD-K27721098-065-02-9
BSPBio_003211
C16H16ClNO2S
CGE
CHEBI:37941
CHEMBL1771
CID60606
CLOPIDOGREL SULFATE
CPD000550475
Clopidogrel
Clopidogrel (INN)
Clopidogrel (TN)
Clopidogrel [BAN:INN]
Clopidogrel [Ban:Inn]
Clopidogrel [INN:BAN]
Clopidogrel bisulfate
Clopidogrel bisulphate
Clopidogrel sulfate
Clopidogrelum
D07729
DB00758
DivK1c_000787
HMS2090O21
HMS502H09
HSDB 7430
IDI1_000787
 
Isocover
KBio1_000787
KBio2_000545
KBio2_003113
KBio2_005681
KBio3_002431
KBioGR_000689
KBioSS_000545
LS-172232
MLS001165708
MLS001195633
MLS001304711
Methyl (+)-(S)-alpha-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4H)-acetate
MolPort-002-885-817
MolPort-003-845-991
NCGC00163329-02
NINDS_000787
Plavix
Plavix (TN)
SAM002589956
SMR000550475
SPBio_000463
SR 25990
STK580572
STOCK5S-27782
Spectrum2_000512
Spectrum3_001606
Spectrum4_000175
Spectrum_000105
TL8000400
UNII-A74586SNO7
Zyllt
clopidogrel
clopidogrel, (+)(S)-isomer
methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
nchem.651-comp8
14Dopamine AntagonistsPhase 4, Phase 11093
15Dopamine AgentsPhase 4, Phase 13836
16Haloperidol decanoatePhase 4, Phase 1147
17
SerotoninPhase 4, Phase 1362750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
18Psychotropic DrugsPhase 4, Phase 3, Phase 16430
19Central Nervous System DepressantsPhase 4, Phase 3, Phase 113403
20Gastrointestinal AgentsPhase 4, Phase 2, Phase 18402
21Serotonin AgentsPhase 4, Phase 13156
22Serotonin AntagonistsPhase 4, Phase 11409
23Antipsychotic AgentsPhase 4, Phase 12401
24Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 123689
25Neurotransmitter AgentsPhase 4, Phase 1, Phase 218340
26AntiemeticsPhase 4, Phase 14022
27Tranquilizing AgentsPhase 4, Phase 3, Phase 14265
28Autonomic AgentsPhase 4, Phase 110150
29Anti-Asthmatic AgentsPhase 4, Phase 13488
30Respiratory System AgentsPhase 4, Phase 14997
31Phosphodiesterase 3 InhibitorsPhase 4133
32Bronchodilator AgentsPhase 42965
33Phosphodiesterase InhibitorsPhase 41289
34Fibrinolytic AgentsPhase 42388
35Neuroprotective AgentsPhase 41716
36Protective AgentsPhase 47443
37Purinergic P2Y Receptor AntagonistsPhase 4793
38Vasodilator AgentsPhase 43543
39Platelet Aggregation InhibitorsPhase 42516
40Purinergic P2 Receptor AntagonistsPhase 4795
41Quetiapine FumaratePhase 4413111974-72-2
42Serotonin 5-HT2 Receptor AntagonistsPhase 4225
43Serotonin Uptake InhibitorsPhase 41587
44sultopridePhase 448
45Fluphenazine enanthatePhase 416
46bromperidolPhase 43
47BenperidolPhase 44
48PerazinePhase 43
49Antidepressive AgentsPhase 42736
50ClopenthixolPhase 46

Interventional clinical trials:

(show top 50)    (show all 63)
idNameStatusNCT IDPhase
1Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction PatientsRecruitingNCT01261832Phase 4
2Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsActive, not recruitingNCT02307396Phase 4
3Posaconazole to Treat Invasive Fungal InfectionsCompletedNCT00033982Phase 3
4Antibiotic Treatment of Gulf War Veterans' IllnessesCompletedNCT00007735Phase 3
5Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer PainActive, not recruitingNCT02240199Phase 3
6Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE SyndromeRecruitingNCT02996448Phase 2
7CAMB/MAT2203 in Patients With Mucocutaneous CandidiasisRecruitingNCT02629419Phase 2
8Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency DiseasesRecruitingNCT01852370Phase 1, Phase 2
9Expanding HIV Testing and Prevention to Reach Vulnerable Young WomenRecruitingNCT02974998Phase 2
10Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 RiskActive, not recruitingNCT01720225Phase 2
11Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)Active, not recruitingNCT01636609Phase 1, Phase 2
12Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) SyndromeTerminatedNCT00527878Phase 2
13Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy VolunteersUnknown statusNCT01259973Phase 1
14Omalizumab to Treat Hyper-IgE (Job's) SyndromeCompletedNCT00260702Phase 1
15Diagnostic Effectiveness of Virtual BronchoscopyCompletedNCT00001515Phase 1
16Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected AdultsCompletedNCT00124007Phase 1
17NFIL3-induced Pathological Enhancement of IgE Class Switch Recombination in Hyper-IgE SyndromeUnknown statusNCT02228941
18Assessment of Quality of Global and Sexual Life and Impact of Surgical and Non Surgical Vaginal Aplasia in Patients With a Rokitansky SyndromeUnknown statusNCT01911884
19Effectiveness Study of Integrative Treatment for Pediatric Community Acquired PneumoniaUnknown statusNCT02362906
20Influence of Light Therapy on Confusion in Patients at the Intensive Care UnitUnknown statusNCT01343433
21A Trial of Clay Weight on the Ear Drum for Patulous Eustachian TubeUnknown statusNCT00933478
22Effect of Different Working Conditions on Risk Factors in Dentists Versus TrainersUnknown statusNCT00521235
23Critical Care Excellence in Sepsis and TraumaUnknown statusNCT01426711
24Learning and Behavior Problems in Children With Chronic Granulomatous Disease and Related DisordersCompletedNCT00005933
25Effectiveness of Physical Therapy Program to Treat Rotator Cuff Disorders Among Nursing ProfessionalsCompletedNCT01465932
26Sleep Disorders Management, Health and Safety in PoliceCompletedNCT00207285
27Case-control Study on Individual Risk Factors of CTSCompletedNCT03166033
28Effectiveness of an Intervention for Prevention and Treatment of Burnout in Primary CareCompletedNCT01870154
29Level of Burn Out of Surgical Residents Working in All Hospitals of LahoreCompletedNCT02206139
30Level of Burn Out of Surgical Residents Working in Government Hospitals of LahoreCompletedNCT02204592
31Comprehensive Police Fatigue Management ProgramCompletedNCT00246051
32Fire Fighter Fatigue Management Program: Operation Healthy SleepCompletedNCT01988129
33Health Protection & Promotion for Oregon Correctional OfficersCompletedNCT02098603
34Stress Free Now, a Mind-body Reduction Program for NursesCompletedNCT01796054
35The Effects of Work Schedule and Sleep Patterns on Caregivers' HealthCompletedNCT01443156
36Inflammation and Glycation in a General Adult PopulationCompletedNCT01796184
37Can we Reduce Hospital Attendance Without Compromising Care by the Use of Telephone ConsultationCompletedNCT00129701
38Risk Assessment of Long-Haul Truck DriversCompletedNCT00381992
39Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in JapanCompletedNCT00001712
40Community-Based Peer Facilitator InterventionCompletedNCT02496793
41Integration of HIV Care and Treatment Into Antenatal Care in Migori District, KenyaCompletedNCT00931216
42Motiv82Change: an HIV Prevention Study for Young Latino MenCompletedNCT00877695
43Study of Clinical Features and Genetics of Hyperimmunoglobulin E Recurrent InfectionRecruitingNCT00006150
44Study of Mycobacterial InfectionsRecruitingNCT00018044
45Collection of Lung Fluid and Tissue Samples for ResearchRecruitingNCT00471250
46Human Immunity Against Staphylococcus Aureus Skin InfectionRecruitingNCT02262819
47Studies of Skin Microbes in Healthy People and in People With Skin ConditionsRecruitingNCT00605878
48Detection and Characterization of Infections and Infection SusceptibilityRecruitingNCT00404560
49Study of Autoimmune Lymphoproliferative Syndrome (ALPS)RecruitingNCT00001350
50Cardiovascular Risk Prevention Among Night WorkersRecruitingNCT02899442

Search NIH Clinical Center for Hyper-Ige Recurrent Infection Syndrome


Cochrane evidence based reviews: job syndrome

Genetic Tests for Hyper-Ige Recurrent Infection Syndrome

About this section

Genetic tests related to Hyper-Ige Recurrent Infection Syndrome:

id Genetic test Affiliating Genes
1 Hyperimmunoglobulin E Syndrome27
2 Autosomal Dominant Hyper Ige Syndrome24 STAT3

Anatomical Context for Hyper-Ige Recurrent Infection Syndrome

About this section

MalaCards organs/tissues related to Hyper-Ige Recurrent Infection Syndrome:

36
Skin, Bone, Lung, Eye

Publications for Hyper-Ige Recurrent Infection Syndrome

About this section

Articles related to Hyper-Ige Recurrent Infection Syndrome:

idTitleAuthorsYear
1
Coronary abnormalities in hyper-IgE recurrent infection syndrome: depiction at coronary MDCT angiography. (19933621)
2009
2
Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome. (17098478)
2007

Variations for Hyper-Ige Recurrent Infection Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Hyper-Ige Recurrent Infection Syndrome:

70 (show all 14)
id Symbol AA change Variation ID SNP ID
1STAT3p.Arg382LeuVAR_037365rs113994136
2STAT3p.Arg382GlnVAR_037366rs113994136
3STAT3p.Arg382TrpVAR_037367rs113994135
4STAT3p.Phe384LeuVAR_037368
5STAT3p.Phe384SerVAR_037369
6STAT3p.Thr389IleVAR_037370rs397514766
7STAT3p.Arg423GlnVAR_037371rs113994137
8STAT3p.His437TyrVAR_037372
9STAT3p.Ser611AsnVAR_037375
10STAT3p.Phe621ValVAR_037376
11STAT3p.Thr622IleVAR_037377
12STAT3p.Val637LeuVAR_037378
13STAT3p.Val637MetVAR_037379rs113994139
14STAT3p.Tyr657CysVAR_037381rs193922721

Clinvar genetic disease variations for Hyper-Ige Recurrent Infection Syndrome:

5 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1STAT3NM_ 139276.2(STAT3): c.1387_ 1389delGTG (p.Val463del)deletionPathogenicrs113994138GRCh37Chr 17, 40477056: 40477058
2STAT3NM_ 139276.2(STAT3): c.1144C> T (p.Arg382Trp)SNVPathogenicrs113994135GRCh37Chr 17, 40481661: 40481661
3STAT3NM_ 139276.2(STAT3): c.1145G> A (p.Arg382Gln)SNVPathogenicrs113994136GRCh37Chr 17, 40481660: 40481660
4STAT3NM_ 139276.2(STAT3): c.1268G> A (p.Arg423Gln)SNVPathogenicrs113994137GRCh37Chr 17, 40481441: 40481441
5STAT3STAT3, ARG383LEUSNVPathogenic
6STAT3NM_ 139276.2(STAT3): c.1909G> A (p.Val637Met)SNVPathogenicrs113994139GRCh37Chr 17, 40474492: 40474492
7STAT3NM_ 139276.2(STAT3): c.1003C> T (p.Arg335Trp)SNVLikely pathogenicrs193922716GRCh37Chr 17, 40485737: 40485737
8STAT3NM_ 139276.2(STAT3): c.1243G> A (p.Glu415Lys)SNVPathogenic/ Likely pathogenicrs193922717GRCh37Chr 17, 40481466: 40481466
9STAT3NM_ 139276.2(STAT3): c.1772A> T (p.Lys591Met)SNVLikely pathogenicrs193922719GRCh37Chr 17, 40475138: 40475138
10STAT3NM_ 139276.2(STAT3): c.1780G> A (p.Glu594Lys)SNVLikely pathogenicrs193922720GRCh37Chr 17, 40475130: 40475130
11STAT3NM_ 139276.2(STAT3): c.1970A> G (p.Tyr657Cys)SNVLikely pathogenicrs193922721GRCh37Chr 17, 40474431: 40474431
12STAT3NM_ 139276.2(STAT3): c.2134T> C (p.Cys712Arg)SNVLikely pathogenicrs193922722GRCh37Chr 17, 40469210: 40469210
13STAT3NM_ 139276.2(STAT3): c.1166C> T (p.Thr389Ile)SNVPathogenicrs397514766GRCh37Chr 17, 40481639: 40481639

Expression for genes affiliated with Hyper-Ige Recurrent Infection Syndrome

About this section
Search GEO for disease gene expression data for Hyper-Ige Recurrent Infection Syndrome.

Pathways for genes affiliated with Hyper-Ige Recurrent Infection Syndrome

About this section

Pathways related to Hyper-Ige Recurrent Infection Syndrome according to GeneCards Suite gene sharing:

(show all 24)
idSuper pathwaysScoreTop Affiliating Genes
19.5STAT3, TYK2
29.5STAT3, TYK2
39.5STAT3, TYK2
49.5STAT3, TYK2
5
Show member pathways
9.5STAT3, TYK2
69.5STAT3, TYK2
79.5STAT3, TYK2
8
Show member pathways
9.5STAT3, TYK2
9
Show member pathways
9.5STAT3, TYK2
109.5STAT3, TYK2
11
Show member pathways
9.5STAT3, TYK2
129.5STAT3, TYK2
13
Show member pathways
9.5STAT3, TYK2
149.4IRAK4, STAT3
15
Show member pathways
9.2IL17A, STAT3
16
Show member pathways
8.9IRAK4, STAT3, TYK2
17
Show member pathways
8.9IRAK4, STAT3, TYK2
18
Show member pathways
8.7IL17A, STAT3, TYK2
198.7IL17A, STAT3, TYK2
20
Show member pathways
8.7IL17A, STAT3, TYK2
21
Show member pathways
8.7IL17A, STAT3, TYK2
22
Show member pathways
8.7IL17A, STAT3, TYK2
238.1IL17A, IRAK4, STAT3, TYK2
24
Show member pathways
8.1IL17A, IRAK4, STAT3, TYK2

GO Terms for genes affiliated with Hyper-Ige Recurrent Infection Syndrome

About this section

Biological processes related to Hyper-Ige Recurrent Infection Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1phosphorylationGO:00163109.1IRAK4, STAT3, STK4, TYK2
2protein phosphorylationGO:00064688.8IRAK4, STK4, TYK2

Molecular functions related to Hyper-Ige Recurrent Infection Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein kinase activityGO:00046728.8IRAK4, STK4, TYK2

Sources for Hyper-Ige Recurrent Infection Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet